Henry Schein (HSIC) Earns Hold Rating from Leerink Swann

Henry Schein (NASDAQ:HSIC)‘s stock had its “hold” rating restated by equities researchers at Leerink Swann in a note issued to investors on Tuesday.

A number of other brokerages have also issued reports on HSIC. Zacks Investment Research lowered Henry Schein from a “hold” rating to a “sell” rating in a report on Monday, November 13th. Robert W. Baird set a $95.00 price target on Henry Schein and gave the company a “buy” rating in a report on Thursday, October 19th. Stifel Nicolaus lowered their price target on Henry Schein from $89.00 to $77.00 and set a “hold” rating for the company in a report on Tuesday, November 7th. Craig Hallum upgraded Henry Schein from a “hold” rating to a “buy” rating in a report on Tuesday, November 7th. Finally, Evercore ISI initiated coverage on Henry Schein in a report on Thursday, January 4th. They issued an “outperform” rating and a $81.00 price target for the company. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have assigned a buy rating to the company. Henry Schein currently has an average rating of “Hold” and an average target price of $84.23.

Shares of Henry Schein (NASDAQ HSIC) opened at $68.43 on Tuesday. The company has a quick ratio of 0.86, a current ratio of 1.55 and a debt-to-equity ratio of 0.30. The stock has a market capitalization of $10,577.16, a P/E ratio of 18.90, a P/E/G ratio of 1.73 and a beta of 1.00. Henry Schein has a twelve month low of $63.01 and a twelve month high of $93.50.

In related news, Director Barry J. Alperin sold 5,796 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $70.76, for a total value of $410,124.96. Following the completion of the transaction, the director now owns 48,172 shares of the company’s stock, valued at $3,408,650.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.19% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. BlackRock Inc. raised its stake in Henry Schein by 0.8% in the fourth quarter. BlackRock Inc. now owns 11,752,750 shares of the company’s stock worth $821,284,000 after buying an additional 95,088 shares in the last quarter. Generation Investment Management LLP raised its stake in Henry Schein by 561.1% in the fourth quarter. Generation Investment Management LLP now owns 11,026,174 shares of the company’s stock worth $770,509,000 after buying an additional 9,358,345 shares in the last quarter. Mackenzie Financial Corp raised its stake in Henry Schein by 53.0% in the fourth quarter. Mackenzie Financial Corp now owns 6,023,557 shares of the company’s stock worth $420,926,000 after buying an additional 2,085,324 shares in the last quarter. Alecta Pensionsforsakring Omsesidigt raised its stake in Henry Schein by 112.0% in the third quarter. Alecta Pensionsforsakring Omsesidigt now owns 5,313,980 shares of the company’s stock worth $435,693,000 after buying an additional 2,806,990 shares in the last quarter. Finally, Janus Henderson Group PLC raised its stake in Henry Schein by 92.1% in the third quarter. Janus Henderson Group PLC now owns 2,814,636 shares of the company’s stock worth $230,777,000 after buying an additional 1,349,333 shares in the last quarter. 91.15% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.chaffeybreeze.com/2018/02/15/henry-schein-hsic-earns-hold-rating-from-leerink-swann.html.

About Henry Schein

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Analyst Recommendations for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply